title: An N-terminal molecular form of parathyroid hormone (PTH) distinct from hPTH(1 84) is overproduced in parathyroid carcinoma.
abstract: BACKGROUND
  A new parathyroid hormone (PTH) species, the N-terminal PTH form (N-PTH), is distinct from intact human PTH of 84 amino acid residues [hPTH(1-84)] and is recognized in a 3rd-generation assay of "whole" PTH (wPTH; the 1-2 epitope) but not in a 2nd-generation assay of "total" PTH (tPTH; the 12-18 epitope). N-PTH usually represents <15% of wPTH but can be overproduced in severe primary hyperparathyroidism (PHPT) and secondary hyperparathyroidism. We investigated whether N-PTH is also overproduced in parathyroid cancer and whether N-PTH concentration is influenced by calcimimetic therapy.
  
  
  METHODS
  We studied 8 patients with parathyroid carcinoma before and at week 16 of cinacalcet therapy, 6 patients with PHPT, and 6 control individuals. We fractionated sera with HPLC and analyzed fractions with the 2 assays to quantify hPTH(1-84), N-PTH, and non-(1-84) PTH fragments.
  
  
  RESULTS
  Half of parathyroid carcinoma patients had an increased wPTH:tPTH ratio [mean (SD), 1.35 (0.29)]; the others had a typical ratio [0.72 (0.12)]. HPLC fractionation of sera from 2 high-ratio patients confirmed N-PTH overproduction [65% (12%) of wPTH]. The N-PTH fraction was <15% of wPTH in PHPT and healthy individuals. Calcimimetic therapy appreciably reduced calcium concentrations in parathyroid carcinoma patients but had little influence on PTH concentration, the wPTH:tPTH ratio, or the PTH HPLC profile.
  
  
  CONCLUSIONS
  N-PTH is overproduced in some parathyroid cancer patients, but calcimimetic therapy does not influence its production. The clinical implications of this finding in parathyroid carcinoma await additional studies with an emphasis on N-PTH's biological activity and with larger numbers of patients.
authors.affiliation: College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA.
authors.forename: Mishaela R
authors.initials: MR
authors.lastname: Rubin
authors.forename: Shonni J
authors.initials: SJ
authors.lastname: Silverberg
authors.forename: Pierre
authors.initials: P
authors.lastname: D'Amour
authors.forename: Jean-Hugues
authors.initials: JH
authors.lastname: Brossard
authors.forename: Louise
authors.initials: L
authors.lastname: Rousseau
authors.forename: James
authors.initials: J
authors.lastname: Sliney
authors.forename: Tom
authors.initials: T
authors.lastname: Cantor
authors.forename: John P
authors.initials: JP
authors.lastname: Bilezikian
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000096:biosynthesis*; D002851:Chromatography, High Pressure Liquid; D000069449:Cinacalcet; D005260:Female; D006801:Humans; D049950:Hyperparathyroidism, Primary / Q000188:drug therapy / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009281:Naphthalenes / Q000627:therapeutic use; D010281:Parathyroid Hormone / Q000096:biosynthesis* / Q000097:blood; D010282:Parathyroid Neoplasms / Q000188:drug therapy / Q000378:metabolism*; D010446:Peptide Fragments / Q000096:biosynthesis* / Q000097:blood
chemical_list: D014408:Biomarkers, Tumor; D009281:Naphthalenes; D010281:Parathyroid Hormone; D010446:Peptide Fragments; C040288:amino-terminal parathyroid hormone; D000069449:Cinacalcet